IXICO selected by Cyclerion for new Alzheimer's disease study
For the study, IXICO will provide advanced neuroimaging solutions involving structural magnetic resonance imaging (MRI), diffusion MRI (dMRI), resting state functional MRI (rs-fMRI) and arterial spin labelling (ASL).
- For the study, IXICO will provide advanced neuroimaging solutions involving structural magnetic resonance imaging (MRI), diffusion MRI (dMRI), resting state functional MRI (rs-fMRI) and arterial spin labelling (ASL).
- Alzheimer's disease (AD) is a progressive degenerative disease affecting approximately 50 million people worldwide with devastating physical, emotional and financial impact to patients and families.
- Lammert Albers, Chief Commercial Officer of IXICO, commented: "IXICO is thrilled to be chosen by Cyclerion Therapeutics and take part in this important Alzheimer's disease trial.There are currently no means to prevent or delay onset, slow progression or meaningfully improve symptoms of this devastating disease.
- Chris Wright, Chief Medical Officer at Cyclerion, said:"We are pleased to leverage IXICO's neuroimaging services in this new Alzheimer's disease study.